ArticleBMC infectious diseases2026
Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global rise of antimicrobial resistance has become a major public health concern. However, data on the clinical course and outcomes of infections caused by pandrug-resistant (PDR) bacteria in children remain limited. This study aimed to compare the clinical characteristics and treatment outcomes of PDR Acinetobacter baumannii and Klebsiella pneumoniae infections in pediatric patients.
methodsWe retrospectively analyzed pediatric cases with PDR A. baumannii and K. pneumoniae infections diagnosed between 2020 and 2023 in a tertiary-care center. Demographic characteristics, infection sites, clinical findings, and outcomes were compared between the two groups using appropriate statistical tests.
resultsPDR K. pneumoniae infections occurred in significantly younger children (p = 0.004). PDR K. pneumoniae episodes most commonly involved pneumonia (47.4%) or bloodstream infection (42.1%), with mortality rates of 15.8%. PDR A. baumannii episodes were most frequently associated with pneumonia (65.3%), with mortality rates of 7.7%. Recurrence rates were similar between the two groups (36.8% vs. 26.9%; p = 0.478), and none of the recurrent infections resulted in death. Fever duration was longer in the PDR A. baumannii group (p = 0.009), whereas co-infections and complications were numerically more frequent but did not reach statistical significance (respectively; p = 0.06 and p = 0.08). Ceftazidime-avibactam (CZA) resistance was observed in 63.2% of PDR K. pneumoniae isolates, and all recurrent PDR K. pneumoniae episodes were CZA-resistant; no deaths occurred among recurrent episodes in either group.
conclusionsPDR A. baumannii and K. pneumoniae infections showed comparable severity and mortality in children, although K. pneumoniae affected younger patients and A. baumannii was associated with longer fever duration. Both pathogens were typically identified after prolonged hospitalization and were closely linked to intensive care exposure. The high rate of CZA resistance among PDR K. pneumoniae isolates, including all recurrent PDR K. pneumoniae episodes, was a clinically important finding that may further limit therapeutic options. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.